LUGPA 2026 BPH CME Series-BPH Webinar 2

Video Transcription

Video Summary

This panel discussion focused on treatment options for benign prostatic hyperplasia (BPH), emphasizing shared decision-making, proper patient evaluation, and choosing the right intervention for the right prostate size and anatomy. The speakers reviewed a case of a 60-year-old man with moderate symptoms, a 55-gram prostate, and worsening response to tamsulosin. They stressed completing a workup with tests like uroflow, UroCuff, cystoscopy, and assessing the importance of ejaculatory preservation. For this type of patient, they generally favored minimally invasive surgical therapies such as prostatic urethral lift (UroLift), while noting that PAE may be less ideal for smaller prostates.<br /><br />The panel compared medical therapy, minimally invasive options, and resective procedures, discussing the strengths and limitations of UroLift, Rezūm, ITIND, nitinol stents, TURP, HoLEP, Aquablation, and prostatic artery embolization (PAE). They highlighted that medical therapy is often overused and should be monitored closely with symptom scores and pressure-flow testing. The speakers also noted that earlier intervention may improve outcomes and help preserve bladder function. The session ended by previewing larger-prostate cases for the next discussion.

Keywords

benign prostatic hyperplasia

BPH treatment

shared decision-making

prostate evaluation

uroflow testing

cystoscopy

ejaculatory preservation

UroLift

minimally invasive surgical therapy